[0] Chairman of Molecular Diagnostics, Inc. Incorrectly Listed as Seller of Company Stock.Business Editors, Health/Medical Writers CHICAGO--(BW HealthWire)--Feb. 28, 2002 Molecular Diagnostics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :MCDG) announced today that a Form 144 filing submitted by Merrill Lynch Merrill Lynch & Co., Inc. (NYSE: MER TYO: 8675 ), through its subsidiaries and affiliates, provides capital markets services, investment banking and advisory services, wealth management, asset management, insurance, banking and related products and services on a global basis. & Co. Inc. to the Securities and Exchange Commission incorrectly listed Peter Gombrich, Molecular Diagnostics' Chairman of the Board, as having filed to sell 8,500 shares of Molecular Diagnostics' common stock. Mr. Gombrich did not file to sell shares and an amended filing has been submitted by Merrill Lynch & Co. to the Securities and Exchange Commission. About Molecular Diagnostics Molecular Diagnostics develops cost-effective cancer screening systems which can be utilized at the point of care or in a laboratory, to assist in the early detection of cervical, gastrointestinal and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, point-of-care cervical cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. screening system. Other products include SAMBA(TM) Telemedicine software used for medical image processing image processing Set of computational techniques for analyzing, enhancing, compressing, and reconstructing images. Its main components are importing, in which an image is captured through scanning or digital photography; analysis and manipulation of the image, accomplished , database and multimedia case management, telepathology and teleradiology. Molecular Diagnostics also makes certain aspects of its technology available to 3rd parties for development of their own screening systems. Certain statements throughout this release are forward-looking. These statements are based on the Company's current expectations and involve many risks and uncertainties, such as the possibility that clinical trials will not substantiate To establish the existence or truth of a particular fact through the use of competent evidence; to verify. For example, an Eyewitness might be called by a party to a lawsuit to substantiate that party's testimony. the Company's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by Molecular Diagnostics, Inc. with the Securities and Exchange Commission. Molecular Diagnostics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion